Development and Characterization of Gamma Oryzanol Loaded Niosomes
Abstract
Over the past several years, treatment of infectious diseases and immunization has undergone a revolutionary shift. Noisome are vesicles composed of non-ionic surfactants, which are biodegradable, relatively nontoxic, more stable and inexpensive, an alternative to liposomes. Noisome are of nonionic multilamellar vesicular structure of surface-active agents, which is similar to liposomes. This article highlights Ƴ-oryzanol (Oz) exert their antioxidant activity and often associated with lowering level of cholesterol, anti-inflammatory, anti-diabetic and anti-cancer effects. All reformulation studies were performed. The thin-film hydration technique was used for encapsulation of OZ in noisome. More than 85 % entrapment of Oz was achieved. Nearly 90 % drug was released within 24 hours. Formulation was found sterilized. Formulation was found stable after 5 weeks.
References
2. Lee VHL. Controlled Drug Delivery Fundamentals and Applications: Influence of drug properties on design. Marcel Dekker, Inc. New York: 1987;2:16-25.
3. Kushal M, Monali M, Durgavati M, Panchal M, Umesh S, Pragna S. Oral controlled release drug delivery system: An overview. Int. Res. J. Pharm. 2013; 4:70-76.
4. Biju SS, Talegaonkar S, Mishara PR, Khar RK. Indian J. Pharm. Sci. 2010; 210:141—151.
5. Shakya V. Niosomes: A Novel Trend in Drug Delivery. Ijrdp. 2014; 3: 1036-1041.
6. Bagheri A, Chu B, Yaakob H. Niosomal Drug Delivery Systems: Formulation, Preparation and Applications. World Applied Sciences Journal. 2014; 32: 1671-1685.
7. Sudheer P, Kaushik K. Review on Niosomes- A Novel Approach for Drug Targeting, Journal of Pharmaceutical Research. 2015; 1-14.
8. Sankhyan A, Pawar P. Recent Trends in Niosome as Vesicular Drug Delivery System. Journal of Applied Pharmaceutical Science. 2012; 2: 20-32.
9. Gurjar P. Niosome: A Promising Pharmaceutical Drug Delivery. Int. J. Pharm Anal. 2014; 2: 425-431.
10. Vyas SP, Khar RK. Targeted and Control Drug Deliver. CBS Publishers and Distributors, New Delhi (2002), 249—276.
11. Niemiec SM., Ramachandran HZC, Wallach DFH, Weiner N. STP Pharma Sci.1994;4: 145—149.
12. Kiwada H, Niimura H, Fujisaki Y, Yamada S, Kato Y. Chem. Pharm. Bull. 1985;33: 753—759.
13. Guedj C, Pucci B, Zarif L, Coulomb C, Riess J. G, Pavia AA. Chem. Phys. Lipids. 1994; 72:153—173.
14. Sahin NO. Nanomaterials and Nanosystems for Biomedical Applications. Springer, The Netherlands (2007) 67—81.
15. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. J. Pharm. Pharmacol. 1985; 37:863—868.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.